The effect of long-term pamidronate treatment on skeletal morbidity in advanced multiple myeloma

Acta Haematologica Polonica

Volumn 31, Issue 4, 2000, Pages 379-389

  Kraj, M ^a   Poglod R ^a   Pawlikowski, J ^a   Maj, S ^a  

^a INSTITUTE OF HEMATOLOGY AND TRANSFUSION MEDICINE   (Poland)

Author keywords

Bisphosphonates; Multiple myeloma; Osteolytic lesions; Pamidronate

Indexed keywords

ANTINEOPLASTIC AGENT; HEMOGLOBIN; PAMIDRONIC ACID;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BONE ATROPHY; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; LONG TERM CARE; MALE; MULTIPLE MYELOMA; OSTEOLYSIS;

EID: 0034484749     PISSN: 00015814     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. In vitro cytoreductive effects on multiple myeloma cells induced by bisphosphonates
2. Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma
3. Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events
4. Current use of bisphosphonates in oncology
5. Inhibition of osteolytic bone lesions by (3-amino-1-hydroxypropylidene)-1, 1-bisphosphonate (A.P.D.)
6. Failure of oral pamidronate to reduce skeletal morbidity in multiple myeloma: A double-blind placebo-controlled trial
7. Ibandronate reduces osteolytic lesions but not tumor burden in a murine model of myeloma bone disease
8. Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases
9. Bisphosphonates promote apoptosis in murine osteoclasts in vitro and in vivo
10. Patogeneza choroby nowotworowej kości i jej leczenie bisfosfonianami
11. Pamidronate in the treatment and prevention of multiple myeloma bone disease
12. Long-term clodronate treatment reduces skeletal morbidity but does not prolong survival of multiple myeloma patients with osteolysis
13. The effect of long-term pamidronate treatment on skeletal morbidity in advanced multiple myeloma
14. Effect of pamidronate on skeletal morbidity in myelomatosis. Part 1. The results of the first 12 months of pamidronate therapy
15. Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras
16. Use of pamidronate for multiple myeloma osteolytic lesions
17. Single-dose intravenous therapy with pamidronate for the treatment of hypercalcaemia of malignancy: Comparison of 30 -, 60, and 90 - mg dosages
18. Bisphosphonates induce apoptosis in human myeloma cell lines: A novel anti-tumour activity
19. The bisphosphonate incadronate (YM175) causes apoptosis of human myeloma cells in vitro by inhibiting the mevalonate pathway
20. Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families
21. Treatment of bone metastases from breast cancer and myeloma with pamidronate